WELCOME TO The Biotechnology REPORT
Genetic Microdevices Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
LinKinVax technology | February 04, 2022
LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.
LinKinVax is developing a vaccine platform that directly targets dendritic cells.These cells play a crucial role in the immune system, stimulating and regulating immune responses.
The agreement with Inserm Transfert covers industrial and commercial use, and the...
1upHealth | June 07, 2022
MediKarma, Inc, a global leader in an AI-based patient engagement, education and navigation platform, has selected 1upHealth, the market leader offering healthcare's most complete FHIR® data platform, as its interoperability partner to help patients request and acquire their medical records through FHIR-based APIs. Fast Healthcare Interoperability Resources (FHIR®) is the future of healthcare that brings together claims and clinical information in one common standard to drive innovat...
FierceBiotech | February 06, 2020
Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....
Vipergen ApS, Anavo Therapeutics | May 18, 2021
Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE